The results of the phase Ib study (NCT02471846) were disappointing that the combination of navoximod (IDO1 inhibitors) and atezolizumab (anti-PD-L1 agent) failed to improve clinical benefit among patients with various solid tumors, including HNSCC (89). The gene discussed is IDO1; the disease is head and neck squamous cell carcinoma.